Summary
The product FemaWin 2.5, manufactured by PHARM400, underwent independent testing to verify its composition and potency. The sample, submitted by the Manufacturer Pharmaqo Labs mrp@vitamins.to, was analyzed by Janoshik Analytical, a laboratory specializing in pharmaceutical quality control. The analysis confirmed the presence of Stanozolol at a concentration of 2.30 mg. The testing process was completed on 1 February 2024.
This report serves as an educational resource to promote harm reduction and informed decision-making. However, it is important to note that the batch number was not provided, and the sample was submitted by the manufacturer, which may introduce potential biases. Independent third-party testing across multiple batches is recommended to ensure product consistency and reliability.
Detailed Report
Product Overview
- Manufacturer: Pharmaqo Labs
- Product Name: FemaWin 2.5
- Active Ingredient: Stanozolol
- Batch Number: Unknown
- Expiration Date: Not provided
- Delivery Method: Oral
Sample Acquisition and Testing
- Task Number: #38160
- Testing Ordered: 25 January 2024
- Sample Received: 31 January 2024
- Analysis Conducted By: Janoshik Analytical
- Product Submitted By: Pharmaqo Labs (Manufacturer)
- Analysis Paid For By: Pharmaqo Labs (Manufacturer)
Testing Results
- Active Ingredient: Stanozolol
- Measured Concentration: 2.30 mg
- Accuracy: 92.00% (8.00% above the label claim)
- Variance: -8.00%
Verification Details
- Verification URL: https://janoshik.com/tests/38160_XVUX9PRZ1QYF
Evaluation of Manufacturer-Submitted Testing
This analysis confirms the presence of Stanozolol in the tested product. However, the lack of batch information and the fact that the sample was submitted by the Manufacturer Pharmaqo Labs may introduce potential biases. Manufacturer often select optimal batches for testing, which may not fully represent the consistency of products available to consumers. Independent third-party testing across multiple batches is recommended to validate these findings comprehensively.
Conclusion
The analysis confirms that FemaWin 2.5 contains Stanozolol at a concentration of 2.30 mg. While this result reflects accurate dosing for the tested sample, additional testing is necessary to ensure consistent quality across all batches. This report is provided to support educational and harm reduction efforts, helping consumers make informed choices regarding pharmaceutical products.
Disclaimer
This report is published for educational and harm reduction purposes. Manufacturer-submitted testing may involve inherent biases; however, it can still provide useful data when critically assessed alongside third-party or independent results. Readers are encouraged to use this information responsibly.
